ToConceive will be issued with 20mln M Pharma shares, as well as paying a 5% royalty on all sales as payment.
Vancouver-based M Pharma first told investors about this acquisition last month, and is part of the firm’s move into women’s health.
The treatment – an FDA-approved natural conception lubricant – helps increase the chances of fertility.
It is applied to the outside of a woman’s genitalia and stimulates a natural self-produced lubrication (transudate) that balances the pH to help the sperm to survive.
It also gives the sperm the ability – or capacity – to fertilise the ovum for conception, an important process called sperm capacitation.
“This acquisition is our entry into the women’s health market to complement our existing obesity portfolio,” said chief executive Gary Thompson.
“[It] has a 510K FDA clearance, is protected by four U.S. Patent and Trademark Office patents, and is clinically proven to increase a women’s production of transudate.
“This increase in transudate results in significantly higher success rates for couples trying to conceive without the added expense, or stress, associated with assisted reproduction treatments.”
As Thompson alluded to, the lubricant is significantly cheaper than other fertility treatments.
The average cost of IVF Treatment in the US is US$13,000, while three months of this treatment is just $120.
Shares closed on Monday at C$0.04.
Story by ProactiveInvestors